Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two-drug antiretroviral regimens suppress viral load, but three-drug combos may offer additional benefits.
People living with HIV are learning how to cope with a new pandemic.
HIV itself doesn’t raise the risk of getting the new virus, but some HIV-positive people are prone to severe illness.
The observation that there have been Covid-19 infections in HIV+ persons on TDF/TAF argues against a complete protection from these agents.
HIV-positive people appear no more likely to contract the new coronavirus or to become seriously ill.
New database will collect information about cases of the novel coronavirus among people living with HIV.
Drugs used for decades to treat malaria may help people with the new coronavirus, but clinical trials are needed.
The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.
What’s more, reports that Kaletra can fight the novel coronavirus have not been confirmed.
The outbreak of new coronavirus is having a “major impact” on their lives, and many are “very panicked.”
One link between coronaviruses (COVID-19) and the HIV drug Kaletra dates back to the 2003 outbreak of SARS.
Researchers compared outcomes between babies born to HIV-positive mothers exposed to antiretrovirals and those who were not.
Researchers examined outcomes among a group of people in middle- and low-income nations who switched to the integrase inhibitor.
Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
A South African study found that this cost-savings measure did not change the likelihood of viral suppression after 48 weeks.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.